Q3 FY26 revenue grew 23% YoY to $118.4M, beating guidance, with gross margin rising to 52.8% and adjusted EBITDA loss narrowing to $(11.3)M. DNA Synthesis & Protein Solutions and NGS Applications segments both posted strong growth. Adjusted EBITDA breakeven is expected in Q4 FY26.Original document…
Q3 FY26 revenue grew 23% YoY to $118.4M, beating guidance, with gross margin rising to 52.8% and adjusted EBITDA loss narrowing to $(11.3)M. DNA Synthesis & Protein Solutions and NGS Applications segments both posted strong growth. Adjusted EBITDA breakeven is expected in Q4 FY26.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
